GlobeNewswire: Translational Research in Oncology Contains the last 10 of 18 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:04:16ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/03/27/2634854/0/en/NATALEE-TRIO033-Phase-III-trial-demonstrates-ribociclib-significantly-reduces-the-risk-of-recurrence-for-patients-with-early-breast-cancer-at-interim-analysis.html?f=22&fvtc=4&fvtv=44412NATALEE (TRIO033) Phase III trial demonstrates ribociclib significantly reduces the risk of recurrence for patients with early breast cancer, at interim analysis2023-03-27T13:28:42Z<![CDATA[EDMONTON, Alberta, March 27, 2023 (GLOBE NEWSWIRE) -- Translational Research In Oncology (TRIO) today announced positive topline results from NATALEE (TRIO033), a Novartis sponsored Phase III trial of ribociclib plus endocrine therapy (ET) as adjuvant treatment for patients with stages II and III early breast cancer (EBC) at risk of disease recurrence. NATALEE (TRIO033) met its primary endpoint at a pre-planned interim analysis, achieving a statistically significant improvement in invasive disease-free survival (iDFS) in women and men with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) EBC, when compared to ET alone.]]>https://www.globenewswire.com/news-release/2022/04/11/2420195/0/en/TRIO-Obtains-the-Great-Place-to-Work-Certification-in-Uruguay.html?f=22&fvtc=4&fvtv=44412TRIO Obtains the Great Place to Work® Certification in Uruguay2022-04-11T13:30:00Z<![CDATA[-100% of employees consider TRIO Uruguay a great place to work-]]>https://www.globenewswire.com/news-release/2022/04/11/2420195/0/pt/TRIO-recebe-certifica%C3%A7%C3%A3o-Great-Place-to-Work-no-Uruguai.html?f=22&fvtc=4&fvtv=44412TRIO recebe certificação Great Place to Work® no Uruguai2022-04-11T13:30:00Z<![CDATA[-100% dos funcionários consideram o TRIO Uruguai um ótimo lugar para trabalhar-]]>https://www.globenewswire.com/news-release/2022/04/11/2420195/0/es/TRIO-obtiene-la-certificaci%C3%B3n-de-Great-Place-to-Work-en-Uruguay.html?f=22&fvtc=4&fvtv=44412TRIO obtiene la certificación de Great Place to Work® en Uruguay2022-04-11T13:30:00Z<![CDATA[-El 100% de los empleados considera que TRIO Uruguay es un gran lugar para trabajar-]]>https://www.globenewswire.com/news-release/2022/04/06/2417839/0/en/Trio-Named-To-Canada-s-Top-Employer-List-For-Second-Straight-Year.html?f=22&fvtc=4&fvtv=44412Trio Named To Canada’s Top Employer List For Second Straight Year2022-04-06T15:41:22Z<![CDATA[- Third Time Named to Alberta’s Top Employer List -]]>https://www.globenewswire.com/news-release/2021/08/31/2289261/0/en/TRIO-Enrols-First-Patient-in-Global-Phase-3-Giredestrant-Early-Breast-Cancer-Trial.html?f=22&fvtc=4&fvtv=44412TRIO Enrols First Patient in Global Phase 3 Giredestrant Early Breast Cancer Trial2021-08-31T13:00:00Z<![CDATA[EDMONTON, Alberta, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment of first patient in the LidERA Breast Cancer (TRIO045) trial, a Phase 3 randomized, multi-center, open-label global clinical trial of adjuvant endocrine therapy, giredestrant (GDC-9545) sponsored by F. Hoffmann-LaRoche.]]>https://www.globenewswire.com/news-release/2021/07/06/2258068/0/en/TRIO-Completes-Enrolment-for-Phase-2-Giredestrant-Early-Breast-Cancer-Trial-Ahead-of-Schedule.html?f=22&fvtc=4&fvtv=44412TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule2021-07-06T11:00:00Z<![CDATA[58 Clinical Trial Sites, 11 Countries 58 Clinical Trial Sites, 11 Countries]]>https://www.globenewswire.com/news-release/2021/05/20/2233444/0/en/Translational-Research-in-Oncology-TRIO-Appoints-Board-Member.html?f=22&fvtc=4&fvtv=44412Translational Research in Oncology (TRIO) Appoints Board Member2021-05-20T13:00:00Z<![CDATA[Chair of International Cooperation Committee of Korean Cancer Study Group Chair of International Cooperation Committee of Korean Cancer Study Group]]>https://www.globenewswire.com/news-release/2021/04/21/2214060/0/en/TRIO-Completes-Enrollment-of-Phase-III-NATALEE-Breast-Cancer-Clinical-Trial.html?f=22&fvtc=4&fvtv=44412TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial2021-04-21T12:00:00Z<![CDATA[Over 5000 Patients Enrolled in 20 countries Over 5000 Patients Enrolled in 20 countries]]>https://www.globenewswire.com/news-release/2021/01/26/2164631/0/en/Translational-Research-in-Oncology-TRIO-Named-Top-Alberta-Employer-for-Second-Year.html?f=22&fvtc=4&fvtv=44412Translational Research in Oncology (TRIO) Named Top Alberta Employer for Second Year2021-01-26T19:25:16Z<![CDATA[EDMONTON, Alberta, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), a global academic clinical research organization, is pleased to be recognized as one of Alberta’s Top 70 Employers, an editorial competition that recognizes Alberta’s best places to work.]]>